LSE:CHG - Chemring Group is on investors' watchlists as it approaches its financial year end on 31 October 2026 with a record order book, a Leadership handover and fresh US contract wins. The FTSE 250 defence technology group reported an order book of £1,399m at 30 April 2026, covering 91% of expected Revenue for the year.
Several catalysts are lining up. Chief executive Michael Ord will retire on 1 January 2027, with former Babcock executive Tom Newman joining as chief executive designate on 5 October 2026. In June and July, Chemring announced US contracts to restart production at its Alloy Surfaces decoy Business and Supply biological detection systems. The UK Defence Investment Plan, whose delay Chemring had cited, was also published on 30 June 2026. Investors may watch whether a heavily second-half-weighted year is delivered as planned.
Why Chemring Group (CHG) Is in Focus
Chemring has been in focus since early 2025, when Sky News reported that Bain Capital had made a Takeover proposal valued at around 390p a share. The shares jumped on the reports, but no firm offer followed, and Chemring remains an independent company listed on the London Stock Exchange. There is no current takeover approach in the public domain.
Attention has since shifted to operational delivery. Management kept its full-year outlook unchanged at the interim results on 2 June 2026, although the shares fell 5% on the day, according to interactive investor, as profits were hit by delays to UK defence orders.
Chemring remains a FTSE 250 constituent and was not among the changes in the September 2026 FTSE quarterly review.
What Does Chemring Group Do?
Chemring is a UK-headquartered company in the Aerospace & Defence sector, employing around 2,700 people. It reports through two segments.
Countermeasures & Energetics makes expendable decoys that protect aircraft and ships from missile threats, as well as energetic materials, propellants and rocket motors used in munitions and missiles. Its Chemring Nobel business in Norway is a key European supplier of military explosives.
Sensors & Information includes chemical and biological threat detection and Roke, a UK science and technology business focused on cyber, data and electronic warfare. Roke launched its CORTEXA counter-drone system in April 2026.
Latest Developments for CHG
Recent announcements have been dominated by US contracts and leadership changes:
- 25 June 2026: agreements with the US Department of War to restart Manufacturing at Alloy Surfaces in Philadelphia, including a five-year IDIQ contract with a maximum value of $300m and $45m of funding to restart operations
- 30 June 2026: former Kongsberg Gruppen chief executive Geir Håøy appointed chair of Chemring Nobel
- 1 July 2026: a sole-source US contract for the Joint Biological Tactical Detection System, with a $48.8m ceiling and an initial $36.3m order
- 30 July 2026: Michael Ord's retirement and Tom Newman's appointment announced
Chemring said Alloy Surfaces, previously treated as a discontinued operation, will be reclassified as continuing, although it expects no impact on performance in the 2026 and 2027 financial years. Deliveries under the IDIQ contract are expected to begin early in the 2028 financial year.
Ord said "air platform survivability remains mission-critical" as threats escalate.
Financial Performance
For the six months to 30 April 2026, revenue rose 6.5% to £237.3m. Underlying operating profit fell 7.5% to £24.5m, with the Margin narrowing to 10.3%, and underlying Earnings Per Share fell 8% to 6.1p. Statutory profit before tax was £18.8m. The Interim Dividend rose 4% to 2.8p.
The segments diverged sharply. Countermeasures & Energetics lifted underlying operating profit by 31.8% to £26.1m, while Sensors & Information profit fell to £9.6m from £16.1m, reflecting disruption in the UK market.
Net Debt rose to £144.5m, or 1.47 times underlying EBITDA, as Chemring invested £44m in Energetics capacity in the half. Management expects its three capacity programmes, in the US, Scotland and Norway, to add about £100m of annual revenue and £30m of operating profit from 2028.
For the year to 31 October 2025, Chemring reported revenue of £497.5m, underlying operating profit of £73.5m, up 6%, and a total dividend of 8.0p.
Why the FTSE 250 Stock Could Stay in Focus
Chemring could stay in focus because it is closely linked to rising defence budgets across NATO and allied countries. Its record order book gives visibility, with about £1,139m scheduled for 2027 and beyond at 30 April 2026.
The Energetics expansion programme is a longer-term factor. If the new capacity comes on stream as planned, it may lift earnings from 2028. The new US contracts also show Demand for countermeasures and detection technology.
Leadership change adds interest. Investors may watch how Tom Newman approaches strategy, capital allocation and growth when he takes over in January 2027.
Risks Investors Should Watch
Chemring's profits are heavily weighted to the second half, with about 70% of 2026 operating profit expected in that period. Delays to deliveries or customer acceptance could affect the full-year result.
UK government spending remains a risk. Delayed UK orders hurt Sensors & Information in the first half, and the pace at which the Defence Investment Plan converts into contracts is uncertain.
Net debt has increased and first-half cash conversion was 42%, although management expects 80% to 85% for the full year. Large capital projects also carry execution risk, and defence companies face regulatory, export and reputational considerations.
What Could Investors Watch Next?
The financial year ends on 31 October 2026, with full-year results expected thereafter. Investors may watch whether second-half deliveries support the unchanged outlook, whether cash conversion recovers and how quickly UK orders return. Tom Newman's arrival on 5 October 2026 and further contract awards could also be factors to monitor.
Conclusion
Chemring Group is attracting attention because it combines a record order book, exposure to rising defence spending and a leadership transition. Recent US contracts, including the Alloy Surfaces restart and the biological detection award, have added to its pipeline, while the Energetics expansion programme is aimed at lifting earnings from 2028.
However, a weaker first half, higher net debt and dependence on second-half delivery mean the coming months matter. The Bain Capital approach reported in 2025 did not lead to an offer, so the focus for FTSE 250 investors is on Chemring's performance as an independent company.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...